Candel Therapeutics, Inc. (NASDAQ:CADL) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) have received a consensus recommendation of “Moderate Buy” from the nine analysts that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $18.00.

A number of analysts have recently issued reports on CADL shares. Citigroup lowered their price objective on shares of Candel Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a report on Friday, March 13th. Zacks Research upgraded shares of Candel Therapeutics from a “strong sell” rating to a “hold” rating in a report on Friday, May 15th. Cantor Fitzgerald began coverage on shares of Candel Therapeutics in a report on Monday, April 20th. They issued an “overweight” rating on the stock. Wall Street Zen upgraded shares of Candel Therapeutics from a “sell” rating to a “hold” rating in a report on Monday. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $25.00 price objective on shares of Candel Therapeutics in a report on Friday, March 13th.

Institutional Investors Weigh In On Candel Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Moneta Group Investment Advisors LLC raised its stake in shares of Candel Therapeutics by 4.9% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 42,517 shares of the company’s stock worth $240,000 after purchasing an additional 2,000 shares in the last quarter. Invesco Ltd. raised its stake in shares of Candel Therapeutics by 29.0% during the 4th quarter. Invesco Ltd. now owns 15,039 shares of the company’s stock worth $85,000 after purchasing an additional 3,380 shares in the last quarter. Janney Montgomery Scott LLC raised its stake in shares of Candel Therapeutics by 12.6% during the 1st quarter. Janney Montgomery Scott LLC now owns 30,472 shares of the company’s stock worth $149,000 after purchasing an additional 3,400 shares in the last quarter. MetLife Investment Management LLC raised its stake in shares of Candel Therapeutics by 25.5% during the 4th quarter. MetLife Investment Management LLC now owns 19,443 shares of the company’s stock worth $110,000 after purchasing an additional 3,955 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its stake in shares of Candel Therapeutics by 128.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock worth $40,000 after purchasing an additional 4,439 shares in the last quarter. Institutional investors own 13.93% of the company’s stock.

Candel Therapeutics Stock Performance

NASDAQ:CADL opened at $8.30 on Monday. Candel Therapeutics has a fifty-two week low of $4.35 and a fifty-two week high of $9.27. The company has a debt-to-equity ratio of 0.34, a current ratio of 28.05 and a quick ratio of 28.05. The stock has a market capitalization of $608.14 million, a PE ratio of -8.47 and a beta of -0.49. The business’s 50-day simple moving average is $6.50 and its 200-day simple moving average is $5.81.

Candel Therapeutics (NASDAQ:CADL) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.16. Sell-side analysts expect that Candel Therapeutics will post -0.97 earnings per share for the current fiscal year.

About Candel Therapeutics

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.